Mayne Pharma to restate US dermatology net revenue for FY22
Filed with ASX · · 2 pages · English
Watch Mayne Pharma's latest callMayne Pharma Group (ASX:MYX) Q4 2026 Earnings Call · Replay · Aug 26Read the transcript of Mayne Pharma Group (ASX:MYX) Q4 2026 Earnings Call15 February 2023, Adelaide, Australia: The Board of Mayne Pharma Group Limited (ASX: MYX) (Mayne Pharma or the Company) provides an update in relation to the trading performance for the first 4 months of fiscal year 2023 (FY23) (July 2022–October 2022) provided at the Company’s Annual General Meeting (AGM) on 30 November 2022. Mayne Pharma advises that following a detailed review by the Company an
Mayne Pharma Group Ltd. on 6ix
Earlier from Mayne Pharma
- Mayne Pharma and Mithra announce US launch of HALOETTE, a generic version of NUVARING
- Mayne Pharma provides update on capital management timeline
- MYX completes TherapeuticsMD product licensing transaction
- MYX signs license agreement for womens health products
- AGM presentation and business and trading update
Later from Mayne Pharma
- Mayne Pharma announces sale of US retail generics business
- 2022 Half Year Media Release
- 2023 Half Year Investor Presentation
- Mayne Pharma announces cancellation of capital return
- Update on sale of US retail generics portfolio
Follow Mayne Pharma into a list and get an email when it puts out news.
Follow Mayne Pharma